LSIPR 50 2016: Martin Shkreli and Jim Tananbaum

05-10-2016

Martin Shkreli and Jim Tananbaum were selected in the LSIPR 50 2016 publication for their influence on the life sciences industry. Shkreli and Tananbaum were featured in the investment section, as LSIPR reports.

shutterstock-407933107.jpg

Name: Martin Shkreli

Organisation: Formerly of Turing Pharmaceuticals


Martin Shkreli, Jim Tananbaum, Turing Pharmaceuticals, drugs, Foresite Capital, Jazz Pharmaceuticals,

LSIPR